HealthcareFirms.com » Neurologic Disorders

Catalyst Pharmaceutical Partners

admin — Wed, 03 Mar 2010 00:29:30 +0000

Catalyst Pharmaceutical Partners, Inc. is a biopharmaceutical company focused on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of drug addiction and epilepsy. The Company has obtained from Brookhaven National Laboratory an exclusive license for nine patents in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive-compulsive disorders. Catalyst has also in-licensed worldwide rights to Brookhaven’s vigabatrin-related foreign patents or patents pending in more than 30 countries. CPP-109, Catalyst’s version of vigabatrin, has been granted Fast Track status by the U.S. Food & Drug Administration (FDA) for the treatment of cocaine addiction.

Somaxon Pharmaceuticals, Inc.

admin — Tue, 02 Mar 2010 18:40:16 +0000

Somaxon Pharmaceuticals is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area.

Cortex Pharmaceuticals Inc.

admin — Fri, 26 Feb 2010 18:31:21 +0000

Cortex Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs called AMPAKINE molecules targeted towards human central nervous system diseases. AMPAKINE molecules represent a new approach to treating psychiatric disorders, neurological diseases and brain mediated breathing disorders. AMPAKINE compounds are small drug-like molecules that positively modulate the AMPA-type glutamate receptor complex, amplifying the effect of the most prominent brain neurotransmitter, glutamate leading to excitation of multiple brain circuits that effect learning and memory, attention, and a unique brain stem structure thought to be responsible for maintaining breathing.

AVI Biopharma, Inc.

admin — Fri, 26 Feb 2010 18:31:21 +0000

AVI BioPharma is focused on the discovery and development of RNA–based medicines utilizing proprietary derivatives of its antisense chemistry (morpholino-modified phosphorodiamidate oligomers or PMOs) that can be applied to a wide range of diseases and genetic disorders through several distinct mechanisms of action. Unlike other RNA therapeutic approaches, AVI’s antisense technology has been used to directly target both messenger RNA (mRNA) and its precursor (pre-mRNA), allowing for both up- and down-regulation of targeted genes and proteins. AVI’s RNA–based drug programs are being evaluated for the treatment of Duchenne muscular dystrophy, including an ongoing systemic Phase 1b/2 clinical trial of exon skipping with AVI-4658. AVI’s antiviral programs have demonstrated promising outcomes in Ebola Zaire and Marburg Musoke virus infections and may prove applicable to other viral targets such as Junín, influenza, HCV or Dengue viruses.

Opexa Therapeutics, Inc.

admin — Sun, 21 Feb 2010 13:59:35 +0000

Opexa Therapeutics, Inc. is dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases. The Company’s leading therapy, Tovaxin®, is an individualized cellular immunotherapy treatment in Phase IIb clinical development for multiple sclerosis (MS). Tovaxin is derived from T-cells isolated from peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin and, thereby, reduces the risk of relapse over time.

Lpath Inc.